Have to say the wording of the reply was quite interesting, in particular point 2. They do not consider the drug or application field used by GSK as material to OBJ.
This doesn't sound too well worded to me. I would expect any decision made by a GSK on any drug or application they have could easily materially affect OBJs shareprice.
Ann: Response to ASX Query , page-13
Add WFL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| WFL (ASX) Chart |
Day chart unavailable